Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated diseases
About Amyl Therapeutics
A preclinical-stage biotechnology company pioneering a breakthrough approach to treat rare and severe peripheral protein misfolding diseases and neurodegenerative diseases.
Our scientists work on a proprietary technology, that is able to bind to various types of amyloid fibrils and induce their clearance.
Our therapies are designed to target multiple misfolded proteins implicated in both peripheral diseases involving systemic protein misfolding pathologies and neurodegenerative diseases.